Rupert Sandbrink

13.3k citations

86 papers · 9.1k indexed · 3 hit papers · h-index 37

Impact in

Ophthalmology top 0.1%
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
Pathology and Forensic Medicine top 0.1%
- Multiple Sclerosis Research Studies

Papers in

Pathology and Forensic Medicine 42
- Multiple Sclerosis Research Studies 41
Ophthalmology 15
- Retinal Diseases and Treatments 15
- Retinal and Optic Conditions 8

Co-authors: Ludwig Kappos Konrad Beyreuther Robert Vitti Alyson J. Berliner Frederik Barkhof Christoph Pohl Colin L. Masters Xavier Montalbán
Journals: Multiple Sclerosis Journal (10 papers)Neurology (9 papers)Ophthalmology (7 papers)Journal of Biological Chemistry (5 papers)The Lancet Neurology (4 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Rupert Sandbrink

83 papers receiving 8.7k citations

Hit Papers

align trajectories log scale

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial 2012 · 884 citations

Peers

Countries citing papers authored by Rupert Sandbrink

Since Specialization

Citations

This map shows the geographic impact of Rupert Sandbrink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rupert Sandbrink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rupert Sandbrink more than expected).

Fields of papers citing papers by Rupert Sandbrink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rupert Sandbrink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rupert Sandbrink. The network helps show where Rupert Sandbrink may publish in the future.

Co-authors

The 25 scholars most cited alongside Rupert Sandbrink, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rupert Sandbrink Line = papers co-authored together Rupert Sandbrink links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial British Journal of Clinical Pharmacology ·Antonia M. Joussen, Sebastián Wolf, Peter K. Kaiser, David S. Boyer, Thomas Schmelter, Rupert Sandbrink, Oliver Zeitz, Gesa Deeg, Annett Richter, Torsten Zimmermann, Joachim Hoechel, Ulf Buetehorn, Walter Schmitt, Brigitte Stemper, Michael Karl Boettger	2018	41
2	A combined phase 2a/b study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) Investigative Ophthalmology & Visual Science ·Antonia M. Joussen, Sebastián Wolf, Peter K. Kaiser, David S. Boyer, Thomas Schmelter, Rupert Sandbrink, Oliver Zeitz, Michael Karl Boettger, Brigitte Stemper	2016	4
3	Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study Journal of Neurology ·Christian Lampl, Stefan Nagl, Barry G.W. Arnason, Gıancarlo Comı, Paul O’Connor, Stuart D. Cook, Douglas Jeffery, Ludwig Kappos, Massimo Filippi, K. Beckmann, Timon Bogumil, Christoph Pohl, Rupert Sandbrink, Hans Hartung	2013	8
4	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT Journal of Neurology Neurosurgery & Psychiatry ·Gilles Edan, Ludwig Kappos, Xavier Montalbán, Chris H. Polman, Mark S. Freedman, Hans‐Peter Hartung, David Miller, Frederik Barkhof, Jean‐Louis Herrmann, Vivian Lanius, Brigitte Stemper, Christoph Pohl, Rupert Sandbrink, Dirk Pleimes, (unknown)	2013	57
5	VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study British Journal of Ophthalmology ·Frank G. Holz, Johann Roider, Yuichiro Ogura, Jean‐François Korobelnik, Christian Simader, Georg Groetzbach, Robert Vitti, Alyson J. Berliner, Florian Hiemeyer, K. Beckmann, Oliver Zeitz, Rupert Sandbrink	2013	181
6	Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis JAMA Neurology ·Hans Hartung, Lawrence Steinman, Douglas S. Goodin, Giancarlo Comi, Stuart D. Cook, Massimo Filippi, Paul O’Connor, Douglas Jeffery, Ludwig Kappos, Robert C. Axtell, Volker Knappertz, Timon Bogumil, Susanne Schwenke, Ed Croze, Rupert Sandbrink, Christopher Pohl	2013	28
7	Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss UCL Discovery (University College London) ·Alberto Ascherio, Kassandra L. Munger, Chantal Simon, Ludwig Kappos, CH Polman, HP Hartung, D. H. Miller, Xavier Montalbán, Gilles Edan, Frederik Barkhof, Richard White, Rupert Sandbrink, Christoph Pohl	2012	2
8	Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study Investigative Ophthalmology & Visual Science ·Frank G. Holz, Yuichiro Ogura, Johann Roider, Jean‐François Korobelnik, Brigitte Stemper, Robert Vitti, Alyson J. Berliner, Florian Hiemeyer, Rupert Sandbrink, Oliver Zeitz	2012	4
9	Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies Journal of Neuroinflammation ·Hans-Peter Hartung, Bernd C. Kieseier, Douglas S. Goodin, Barry G.W. Arnason, Gıancarlo Comı, Stuart D. Cook, Massimo Filippi, Douglas Jeffery, Ludwig Kappos, Timon Bogumil, Brigitte Stemper, Rupert Sandbrink, Yukiko Nakada, Haruhiko Nakajima, Susanne Schwenke, Stephan Lehr, Jürgen F. Heubach, Christoph Pohl, Joachim Reischl	2012	6
10	Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion Ophthalmology ·David S. Boyer, Jeffrey S. Heier, David M. Brown, W. Lloyd Clark, Robert Vitti, Alyson J. Berliner, Georg Groetzbach, Oliver Zeitz, Rupert Sandbrink, Xiaoping Zhu, K. Beckmann, Julia A. Haller	2012	199
11	Long-term effect of early treatment with interferon-beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial UCL Discovery (University College London) ·(unknown), Ludwig Kappos, Xavier Montalbán, C. Polman, Mitchel Freedman, HP Hartung, David Miller, Frederik Barkhof, Lanius, (unknown), Brigitte Stemper, Christoph Pohl, Rupert Sandbrink, Dirk Pleimes	2011	1
12	Primary Results of an International Phase III Study Using Intravitreal VEGF Trap-Eye Compared to Ranibizumab in Patients with Wet AMD (VIEW 2) Investigative Ophthalmology & Visual Science ·Ursula Schmidt‐Erfurth, Victor Chong, Bernd Kirchhof, Jean‐François Korobelnik, András Papp, Majid Anderesi, Georg Groetzbach, Bernd Sommerauer, Rupert Sandbrink, Yuichiro Ogura	2011	7
13	Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis Neuroradiology ·I.J. van den Elskamp, Barry P. Boden, Vincenzo Dattola, Dirk L. Knol, Massimo Filippi, Ludwig Kappos, Franz Fazekas, K. Wagner, Christoph Pohl, Rupert Sandbrink, Chris H. Polman, Bernard M.J. Uitdehaag, Frederik Barkhof	2010	22
14	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome BMC Neurology ·Jessica Nielsen, Christoph Pohl, Chris H. Polman, Frederik Barkhof, Mark S. Freedman, Gilles Edan, David H. Miller, Lars Bauer, Rupert Sandbrink, Ludwig Kappos, Bernard M.J. Uitdehaag	2009	16
15	250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study The Lancet Neurology ·Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, Gıancarlo Comı, Stuart D. Cook, Douglas S. Goodin, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Francis Boateng, В. Л. Филиппов, Maria Groth, Volker Knappertz, Christian Kraus, Rupert Sandbrink, Christoph Pohl, Timon Bogumil	2009	295
16	Betaferon (R)/betaseron (R) in newly emerging multiple sclerosis for initial treatment (benefit): Effects of early vs. delayed treatment with interferon beta-1B UCL Discovery (University College London) ·HP Hartung, Ludwig Kappos, C. Polman, Gilles Edan, D. H. Miller, Xavier Montalbán, Frederik Barkhof, Lars Bauer, S. Dahms, Christoph Pohl, Rupert Sandbrink	2007	0
17	Genomics and proteomics: role in the management of multiple sclerosis Journal of Neurology ·Ludwig Kappos, Lutz Achtnichts, Frank Dahlke, Jens Kühle, Yvonne Naegelin, Rupert Sandbrink, Raija L.P. Lindberg	2005	16
18	Expression of the APP Gene Family in Brain Cells, Brain Development and Aging Gerontology ·Rupert Sandbrink, Ursula Mönning, Colin L. Masters, Konrad Beyreuther	1997	20
19	Regulation of APP Expression, Biogenesis and Metabolism by Extracellular Matrix and Cytokinesa Annals of the New York Academy of Sciences ·Konrad Beyreuther, Gerd Multhaup, U. Mönning, Rupert Sandbrink, Dirk Beher, Lars Hesse, David H. Small, Colin L. Masters	1996	19
20	APP Gene Family Alternative Splicing Generates Functionally Related Isoformsa Annals of the New York Academy of Sciences ·Rupert Sandbrink, Colin L. Masters, Konrad Beyreuther	1996	85

About Rupert Sandbrink

Rupert Sandbrink is a scholar working on Pathology and Forensic Medicine, Ophthalmology, Rheumatology, Neurology and Physiology, having authored 86 papers that have together received 9.1k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (41 papers), Alzheimer's disease research and treatments (17 papers), Retinal Diseases and Treatments (15 papers), Systemic Lupus Erythematosus Research (15 papers), Peripheral Neuropathies and Disorders (12 papers), Polyomavirus and related diseases (9 papers), Retinal and Optic Conditions (8 papers) and Retinal Imaging and Analysis (7 papers). The work is most often cited by research in Ophthalmology (3.5k citations), Pathology and Forensic Medicine (3.7k citations), Radiology, Nuclear Medicine and Imaging (2.8k citations), Neurology (1.8k citations) and Rheumatology (1.3k citations). Rupert Sandbrink has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Ludwig Kappos, Konrad Beyreuther, Robert Vitti, Alyson J. Berliner, Frederik Barkhof, Christoph Pohl, Colin L. Masters, Xavier Montalbán, Gilles Edan and Jeffrey S. Heier. Their work appears in journals such as Multiple Sclerosis Journal, Neurology, Ophthalmology, Journal of Biological Chemistry and The Lancet Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact